Showing 5641-5650 of 6963 results for "".
- UCB Presents New Data for Cimzia, Investigational Bimekizumabhttps://practicaldermatology.com/news/ucb-presents-new-data-for-cimzia-investigational-bimekizumab/2460193/Data on the use of UCB’s Cimzia (certolizumab pegol), in psoriasis and psoriatic arthritis (PsA) as well as Phase 2 data for the company’s investigational molecule bimekizumab have been presented at the 28thEuropean Academy of Dermatology and Venereology congress (EADV) in Madrid. Cim
- Data Show Long-term Benefit for Sun Pharma's Ilumyahttps://practicaldermatology.com/news/data-show-long-term-benefit-for-sun-pharmas-ilumya-1/2460189/Long-term follow-up data from ILUMYA® (tildrakizumab-asmn) Phase 3 reSURFACE 1 and 2 trials showed that the significant response rates seen in the initial 52 and 64 weeks, respectively, were maintained over four years for people with moderate-to-severe plaque psoriasis. More than half of
- Altreno: Exclusive Size Available for Dermatologist Dispensinghttps://practicaldermatology.com/news/altreno-exclusive-size-available-for-dermatologist-dispensing/2460182/Altreno (tretinoin) Lotion, 0.05%, is now available exclusively for physician dispensing in a 20-gram size. Launched last year, Altreno Lotion from Ortho Dermatologics is the first and only tretinoin available in a lotion for the treatment of acne that has been shown to be effectiv
- Expert Second Opinion Improves Reliability of Melanoma Diagnoseshttps://practicaldermatology.com/news/expert-second-opinion-improves-reliability-of-melanoma-diagnoses/2460179/Obtaining a second opinion from pathologists who are board certified or have fellowship training in dermatopathology may improve the accuracy and reliability of diagnosing melanoma, according to a new study in JAMA Network Open. To evaluate the impact of obtaining second o
- EADV News: Psoriasis Largely Undertreated, Travels with Anxietyhttps://practicaldermatology.com/news/eadv-news-psoriasis-largely-undertreated-travels-with-anxiety/2460175/Many psoriasis patients remain un- or undertreated, with an average diagnosis time of five years, according to research presented at the 28th European Dermato-Venereology Society Congress in Madrid. In the study of 650 psoriasis patients in Germany, more than half of patients (56 percen
- Research Substantiates Psoriasis/Non-alcoholic Fatty Liver Disease Linkhttps://practicaldermatology.com/news/research-substantiates-psoriasisnon-alcoholic-fatty-liver-disease-link/2460174/The severity of psoriasis is related to the severity of non-alcoholic fatty liver disease (NAFLD), according to research presented at the 28th European Dermato-Venereology Society Congress in Madrid. Patients with psoriasis and NAFLD had more severe hepatic damage if they had a higher s
- Galderma Advances Phase 3 Clinical Study with Nemolizumab in Moderate to Severe Atopic Dermatitishttps://practicaldermatology.com/news/galderma-advances-phase-3-clinical-study-with-nemolizumab-in-moderate-to-severe-atopic-dermatitis/2460171/Galderma has enrolled the first patients in a new Phase 3 clinical study with nemolizumab, an investigational therapy in adult patients with moderate to severe atopic dermatitis. This randomized, double-blinded, placebo-controlled study will assess the efficacy and safety of nemolizumab in subjec
- Study: Tape Strips Can Assess Biomarkers in Pediatric ADhttps://practicaldermatology.com/news/study-tape-strips-can-assess-biomarkers-in-pediatric-ad-1/2460167/Tape strips may serve as a minimally invasive approach to assess biomarkers for early-onset pediatric atopic dermatitis (AD), finds a study in JAMA Dermatology. In the study of 51 children younger than 5 years, 21 children had moderate to severe AD with less than 6 months of di
- Daily Almond Consumption May Reduce Facial Wrinkleshttps://practicaldermatology.com/news/daily-almond-consumption-may-reduce-facial-wrinkles/2460165/Snacking on almonds may help postmenopausal women smooth wrinkles from the inside out, according to a new study funded by the Almond Board of California. In this 16-week randomized controlled trial, 28 healthy
- FDA Approves Galderma's Aklief (trifarotene) Cream for Acnehttps://practicaldermatology.com/news/fda-approves-galdermas-aklief-trifarotene-cream-for-acne/2460164/The FDA has approved Galderma's Aklief (trifarotene) Cream, 0.005% for the topical treatment of acne. Aklief Cream is the only topical retinoid that selectively targets retinoic acid receptor (RAR) gamma, the most common RAR found in the skin. Trifarotene is the first new retinoid molecule to